A Phase Ib Dose-Escalation Study of TRC105 in Combination with Pazopanib in Patients with Advanced Soft Tissue Sarcoma

ID Number 14-0091

Principal Investigator(s)

Department(s) or Division(s)
Hematology and Medical Oncology


To evaluate safety and tolerability and determine a recommended phase 2 dose for TRC105 when added to standard dose pazopanib in patients with advanced soft tissue sarcoma.

Contact Information

Recruiting Patients: Yes